|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismTRPV1 modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismTRPV1 antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Clinical Evaluation of MucoPEG™ for Xerostomia
The purpose of this study is to evaluate the effectiveness of the oral rinse comparing to MucoPEG™ and Biotene®.
This is a randomized open-label crossover study with 42 patients receiving treatment. Patients will be randomly assigned to receive either the MucoPEG™ or the Biotene® Dry Mouth Gentle Oral Rinse in the first period. Patients will use the assigned oral rinse two times a day for two weeks. Patients will switch to the other treatment after a wash-out period of one week.
100 Clinical Results associated with RudaCure Co. Ltd.
0 Patents (Medical) associated with RudaCure Co. Ltd.
100 Deals associated with RudaCure Co. Ltd.
100 Translational Medicine associated with RudaCure Co. Ltd.